Clinical Trial Update: Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cytokine-immunotherapy for low-risk myelodysplastic syndrome has completed. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2011-04-14